These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 3914964)

  • 1. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients.
    Isomura S; Suzuki S; Sato Y
    Dev Biol Stand; 1985; 61():531-7. PubMed ID: 3914964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies on efficacy and safety of an acellular pertussis vaccine in Aichi Prefecture, Japan.
    Isomura S
    Dev Biol Stand; 1991; 73():37-42. PubMed ID: 1778331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies on efficacy and safety of acellular pertussis vaccine.
    Isomura S
    Tokai J Exp Clin Med; 1988; 13 Suppl():39-43. PubMed ID: 3078809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against pertussis by Takeda's acellular pertussis vaccine: household contact studies in Kawasaki City, Japan.
    Kato T; Kaku H; Arimoto Y
    Tokai J Exp Clin Med; 1988; 13 Suppl():35-8. PubMed ID: 3078808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calculation of efficacy of acellular pertussis vaccine from the number of pertussis patients and vaccinees in three areas.
    Ohkuni H; Yabiku M; Togawa M; Fukai K; Yosida I; Minekawa Y; Kitamura T
    Dev Biol Stand; 1991; 73():43-9. PubMed ID: 1778332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and serological reactions after immunization of children in Ghana, West Africa, with the Japanese acellular pertussis vaccine.
    Biritwum RB; Isomura S; Ofosu-Amaah S; Sato Y
    Dev Biol Stand; 1985; 61():539-43. PubMed ID: 2872130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring of a whooping cough epidemic 1994/95 in Switzerland using the sentinel notification system. Sentinella Registry].
    Matter HC; Schmidt-Schläpfer G; Zimmermann H
    Schweiz Med Wochenschr; 1996 Aug; 126(34):1423-32. PubMed ID: 8848704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences with acellular pertussis vaccine in Japan and epidemiology of pertussis.
    Kimura M; Kuno-Sakai H
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):263-73. PubMed ID: 3508651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of acellular pertussis vaccine in Japan--comparison of two areas, one area where immunization started at 6 months and the other area at over 2 years of age--Regional Surveillance Committee on Tuberculosis and Infectious Diseases of Osaka.
    Ohkuni H; Kitaura T; Tamai T; Takasugi Y; Sugimoto T; Fukai K
    Tokai J Exp Clin Med; 1988; 13 Suppl():51-4. PubMed ID: 3273619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemiology of pertussis in industrialized countries].
    Baron S; Bégué P; Grimprel E
    Sante; 1994; 4(3):195-200. PubMed ID: 7921686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the change to acellular pertussis vaccine improved or worsened pertussis control?
    Halperin SA; De Serres G
    CMAJ; 2006 Nov; 175(10):1227. PubMed ID: 17098952
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study.
    Okada K; Ohashi Y; Matsuo F; Uno S; Soh M; Nishima S
    Epidemiol Infect; 2009 Jan; 137(1):124-30. PubMed ID: 18474125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis vaccine effectiveness in reducing clinical disease, transmissibility and proportion of cases with a positive culture after household exposure in Brazil.
    Baptista PN; Magalhães V; Rodrigues LC; Rocha MW; Pimentel AM
    Pediatr Infect Dis J; 2006 Sep; 25(9):844-6. PubMed ID: 16940847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany.
    Juretzko P; von Kries R; Hermann M; Wirsing von König CH; Weil J; Giani G
    Clin Infect Dis; 2002 Jul; 35(2):162-7. PubMed ID: 12087522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pertussis: a reemerging infection?].
    Kriz B; Fabiánová K; Maixnerová M; Benes C; Malý M
    Epidemiol Mikrobiol Imunol; 2007 Apr; 56(2):51-65. PubMed ID: 17593802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute efficacy of acellular pertussis vaccines in household settings.
    Storsaeter J; Gustafsson L
    Dev Biol Stand; 1997; 89():153-9. PubMed ID: 9272345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.